A preliminary trial to Study the Effect of Adding Platelet Rich Plasma to Microneedling plus 5-Fluorouracil Therapy in Vitiligo confined to forearms, hands,legs and feet

To Study the Effect of Adding Platelet Rich Plasma to Microneedling plus topical 5-Fluorouracil Therapy in Acral Vitiligo: A Split-body, Preliminary Phase II Randomized Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/11/016487

Enrollment

Registered

2018-11-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Platelet Rich Plasma: adding monthly Platelet-Rich Plasma to the comparator arm intervention Control Intervention1: 5-Fluorouracil plus Microneedling: microneedling done every 2 weeks,

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with a clinical diagnosis of acral vitiligo 2. Lesions distal to elbows and/or knees 3. At least two comparable lesions, or a single large lesion that can be divided into two parts 4.No new lesions/ extension of old lesions for at least 3 months

Exclusion criteria

Exclusion criteria: 1. Progressive vitiligo 2. Segmental vitiligo 3. Children 4. Presence of lesions only on face and neck 5. Pregnancy 6. Keloidal tendency 7. Bleeding diathesis 8.Inability to follow up regularly at fortnightly intervals

Design outcomes

Primary

Measure	Time frame
To compare the extent and time to repigmentation achieved by addition of platelet-rich plasma (PRP) to topical 5-Fluorouracil plus microneedling in acral vitiligo. Timepoint: at 1,3 and 6 months from starting intervention	—

Secondary

Measure	Time frame
Comparison of side effects in the two arms in terms of incidence, severity and durationTimepoint: 1,2,3,6 months	—

Countries

India

Contacts

Public ContactPankhuri Dudani

All India Institute of Medical Sciences

vksiadvl@gmail.com9958114424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026